Deep learning for subtypes identification of pure seminoma of the testis

Kirill E. Medvedev[1,*], Liwei Jia[2], Nick V. Grishin[1,3]

[1]Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

[2]Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

[3]Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

* Corresponding author

E-mail: Kirill.Medvedev@UTSouthwestern.edu

Abstract

Pathological evaluation of each tumor sample is the most crucial process in the clinical diagnosis workflow. Deep learning is a powerful approach that is widely used to increase accuracy and to simplify the diagnosis process. Previously we discovered clinically relevant subtypes (1 and 2) of pure seminoma, which is the most common histological type of testicular germ cell tumors (TGCTs). Here we developed deep learning decision making tool for identification of seminoma subtypes using histopathological slides. We used all available slides for pure seminoma samples from The Cancer Genome Atlas (TCGA). Seminoma regions of interest (ROIs) were annotated by a genitourinary pathologist. Verified ROIs were split into tiles 300x300 pixels, which were used for model training. The model achieved the highest accuracy at the validation step with 0.933 with 0.92 area under the ROC curve.

Introduction

Seminoma is the most common histological subtype of testicular germ cell tumors (TGCT) that has the highest incidence rate within the testicular cancer group [1]. Overall, TGCT is the most common solid cancer among men aged 15-44 years [1] and the second cancer type based on calculation of life years lost per person dying of cancer, after all pediatric cancers [2]. The procedure of seminoma treatment includes orchiectomy followed by platinum-based chemotherapy using cisplatin or radiation therapy [3]. Current treatments show relatively high efficiency and high patient survival rate; however, they also cause around 40 severe adverse long-term side effects including secondary cancers, and death [4]. About 20% of seminoma cases will relapse, and the reason for this phenomenon is unclear [5]. Treatment of relapsed cases using high-dose chemotherapy will aggravate side effects drastically. Recently we discovered two distinct subtypes of pure seminoma of the testis based on omics data [6]. Two identified seminoma subtypes revealed significant differences in rates of loss of heterozygosity, DNA methylation and telomere elongation, level of expression of lncRNA associated with cisplatin resistance, activity of double stranded DNA breaks repair mechanisms and pluripotency stage. We discovered that subtype 2 revealed several molecular features that can be associated with its undergoing differentiation into non-seminomatous lineages of TGCT are more aggressive and required higher dose of chemotherapy drugs [3]. Therefore, we suggested that seminoma subtype 2 might require adjustment of its treatment strategy. We hypothesized that administration of subtype-specific therapy will significantly help to reduce high relapse rate for pure seminoma patients.

Deep learning (DL) is a powerful tool that is capable of extracting previously hidden information directly from routine histopathology images of cancer tissue and can simplify, speed up and

automate clinical decision-making [7]. Performance of modern DL methods applied to

pathological data often exceed performance of pathology specialist [7]. Most of pathologist are

working in the conditions of an extreme work overload [8]. An overworked pathologist can

result in misinterpretation of pathological data that will affect patients' health and life quality.

DL applications aim to simplify and speed up routine pathological workflows and reduce

pathologists' overload burden. Here we applied DL approach to our recent results to develop

decision making tool for identification of pure seminoma subtypes using histopathological slides.

Materials and Methods

Data set preparation

We used all histopathological slides available at The Cancer Genome Atlas (TCGA) data portal for 64 pure seminoma samples (156 slides). Pure seminoma regions of interest (ROIs) were assigned and verified for each slide by a genitourinary specialized pathologist using Aperio ImageScope version 12.1. During our analysis of pure seminoma H&E slides from the TCGA portal, we identified two samples (TCGA-2G-AAG9, TCGA-2G-AAH0), reported as pure seminoma, however, that should be reported as mixed GCT, since they contain other types of GCT (teratoma and embryonal carcinoma) in addition to seminoma (Fig.1). These cases were removed from our data set.

Figure 1. Slide images of samples containing additional types of GCT. (A) TCGA-2G-AAG9. **(B)** TCGA-2G-AAH0. Teratoma tissue is shown in green, embryonal carcinoma in cyan.

Verified ROIs were subsequently split into smaller tiles (300x300 pixels) at 20X magnification and with 50% overlap using DeepPath package [9]. Tiles containing more than 20% of background were removed. Overall, we obtained about 800,000 tiles which were used for model training. Image data augmentation technique was applied to the tiles dataset to create synthetic

variations of the images and to expand the training dataset (Fig.2). We used following

augmentations from the Imgaug library [10]: random rotation by 0°, 90°, 180°, 270°, random

increase and decrease of contrast, brightness and saturation. After augmentation procedures the

total number of tiles reached about 20 million.

Figure 2. Extraction of tiles from annotated whole slide images (WSI) of two subtypes of

pure seminoma.

Training the model

We conducted all computational experiments at BioHPC computing facility (Lyda Hill

Department of Bioinformatics, UT Southwestern Medical Center, TX, USA). TensorFlow

package [11] version 2.5.0 was used for developing DL model based on Convolution Neural

Networks (CNNs) method. The software stack for GPU acceleration included CUDA 11.2 and

cuDNN 8.1. Since we have binary classification goal (seminoma subtypes 1 and 2), we used

Binary Cross Entropy loss function, which is used when there are only two label classes. We

used an Adam optimizer [12] with a learning rate of 0.001. We employed a convolutional neural

network with Inception-v3 [13] architecture with additional dense layer and sigmoid activation.

This architecture has been widely used for analysis of histopathological images using DL

approaches [14]. Neural network was initialized from ImageNet-pretrained [15] weights. Models

training was performed for 40 epochs with 3-fold cross-validation. Tiles belonging to particular

sample were included only in one subset of data – either training or validation.

Statistical analysis

We used the area under receiver operating characteristics (ROC, AUC) curve and accuracy as

evaluation metrics to measure the tile-level performance of developed model. The ROC curve

was defined as false-positive rate (1-specificity) on the x-axis versus true positive rate

(sensitivity or recall) on the y-axis. Specificity = TN / (TN+FP), Sensitivity = TP / (TP+FN),

Accuracy = (TP+TN) / (TP+FP+TN+FN), where FP, FN, TP and TN are false positives, false

negatives, true positives and true negatives, respectively.

Results

Overview of the whole experiment is shown on Figure 3.

Figure 3. Overview of dataset preparation, training and validation process.

At the training stage, the model achieved the highest accuracy with 0.998. Highest achieved validation accuracy was 0.933. We also evaluate our model using area under the ROC curve metric. Our model showed AUC = 0.92 for validation set (Figure 4). Trained model for identification of pure seminoma subtypes is available in open access at GitHub (https://github.com/kirmedvedev/seminoma-subtypes).

Figure 4. Receiver operating characteristic (ROC) curve for validation set.

Discussion

Every sample of solid tumor undergoes detailed analysis by professional pathologist that includes verification of the cancer tissue presence and annotation of tumor regions. This is the key process in the clinical diagnosis routine. Inaccuracies in pathology reports can critically affect the quality of patient care. An audit of pathology reports showed that if a sample size of 50 gives a sample error rate of 2% there is a 95% probability that the true error rate is up to 10.9% [16]. Moreover, up to one-third of clinicians do not always understand pathology reports, which causes misinterpretation and uncertainty in clinical diagnosis [17]. DL approaches applied to histopathological slide images aim to significantly speed up the diagnosis and simplify their implementation into clinical workflow. DL approached were previously applied to TGCTs WSIs to detecting tumor-infiltrating lymphocytes [18], to detect lymphovascular invasion [19].

However, to the best of our knowledge, seminomas and TGCTs histology images have not been

extensively studied using DL methods.

In this report, we present our first version of the DL decision making tool for identification of

pure seminoma subtypes using histopathological slides. We hypothesize that consideration of

seminoma subtypes during development of treatment strategy will potentially improve its clinical

management and implementation of developed model will improve diagnosis accuracy and

exclude potential errors. Our model achieved the highest validation accuracy with 0.933, which

is comparable with accuracy of other DL binary classifiers of histopathological images [20].

Nevertheless, there are certain limitations of developed model. First, current model was

developed using limited dataset. Second, only one architecture type of CNN was tested. In future

work, this model should be verified using expanded dataset and several addition CNN

architecture types.

Competing interests

144 The authors declare that there are no competing interests associated with the manuscript.

Funding

147 The study was supported by the grants (to N.V.G.) from the National Institutes of Health

148 GM127390 and the Welch Foundation I-1505.

CRediT Author Contribution

151 **Kirill E. Medvedev:** Conceptualization, Methodology, Software, Validation, Formal analysis,

152 Investigation, Data Curation, Visualization, Writing - Original Draft, Project administration.

153 **Liwei Jia:** Investigation, Writing - Review & Editing. **Nick V. Grishin:** Resources, Funding

154 acquisition, Writing - Review & Editing.

Acknowledgements

157 Authors are grateful to TCGA data portal for providing access to TGCT datasets. This research

158 was supported in part by the computational resources provided by the BioHPC computing

159 facility located in the Lyda Hill Department of Bioinformatics, UT Southwestern Medical

160 Center, TX. URL: https://portal.biohpc.swmed.edu

References

1. Ghazarian AA, Trabert B, Devesa SS, *et al.* Recent trends in the incidence of testicular germ

cell tumors in the United States. *Andrology* 2015;3:13-8.

2. Howlader N, Noone AM, Krapcho M, *et al*. SEER Cancer Statistics Review, 1975-2017,

National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on

November 2019 SEER data submission, posted to the SEER web site, April 2020.

3. Shin YS, Kim HJ. Current management of testicular cancer. *Korean J Urol* 2013;54:2-10.

4. Chovanec M, Lauritsen J, Bandak M, *et al*. Late adverse effects and quality of life in

survivors of testicular germ cell tumour. *Nat Rev Urol* 2021;18:227-45.

5. Warde P, Specht L, Horwich A, *et al*. Prognostic factors for relapse in stage I seminoma

managed by surveillance: a pooled analysis. *J Clin Oncol* 2002;20:4448-52.

6. Medvedev KE, Savelyeva AV, Bagrodia A, *et al*. Integrated molecular analysis reveals two

distinct subtypes of pure seminoma of the testis. *bioRxiv* 2022.

7. Echle A, Rindtorff NT, Brinker TJ, *et al*. Deep learning in cancer pathology: a new generation

of clinical biomarkers. *Br J Cancer* 2021;124:686-96.

8. Fritzsche FR, Ramach C, Soldini D, *et al*. Occupational health risks of pathologists-results

from a nationwide online questionnaire in Switzerland. *BMC Public Health* 2012;12:1-2.

9. Coudray N, Ocampo PS, Sakellaropoulos T, *et al*. Classification and mutation prediction from

non–small cell lung cancer histopathology images using deep learning. *Nat Med*

2018;24:1559-67.

10.   Python   library   for   image   augmentation   in   machine   learning   experiments

https://github.com/aleju/imgaug

11.   Abadi M, Barham P, Chen J, *et al*. Tensorflow: A system for large-scale machine

learning. In12th USENIX symposium on operating systems design and implementation

(OSDI 16) 2016 (pp. 265-283).

12.   Kingma DP, Ba J. Adam: A method for stochastic optimization. *arXiv preprint*

arXiv:1412.6980. 2014.

13.   Szegedy C, Vanhoucke V, Ioffe S, *et al*. Rethinking the inception architecture for

computer vision. InProceedings of the IEEE conference on computer vision and pattern

recognition 2016 (pp. 2818-2826).

14.   Kather JN, Pearson AT, Halama N, *et al*. Deep learning can predict microsatellite

instability directly from histology in gastrointestinal cancer. *Nat Med* 2019;25:1054-6.

15.   Deng J, Dong W, Socher R, *et al*. Imagenet: A large-scale hierarchical image database.

In2009 IEEE conference on computer vision and pattern recognition 2009 (pp. 248-255). Ieee.

16.   Ramsay AD. Errors in histopathology reporting: detection and avoidance. *Histopathology*

1999;34:481-90.

17.   Mirham L, Hanna J, Yousef GM. Addressing the Diagnostic Miscommunication in

Pathology: Old Challenges and Innovative Solutions. *Am J Clin Pathol* 2021;156:521-8.

18.   Linder N, Taylor JC, Colling R, *et al*. Deep learning for detecting tumour-infiltrating

lymphocytes in testicular germ cell tumours. *J Clin Pathol* 2019;72:157-64.

19.   Ghosh A, Sirinukunwattana K, Khalid Alham N, *et al*. The Potential of Artificial

Intelligence to Detect Lymphovascular Invasion in Testicular Cancer. *Cancers (Basel)*

2021;13:1325.

20.   Xu Y, Jiang L, Huang S, *et al*. Dual resolution deep learning network with self-attention

mechanism for classification and localisation of colorectal cancer in histopathological images.

J Clin Pathol 2022.

A TCGA-2G-AAG9   B TCGA-2G-AAH0

WSI of seminoma subtype 1

WSI of seminoma subtype 2

20X tiles

20X tiles

ROC curve